Wang Shen

Dr.Shen is co-inventor of our EO1000 and EO2000 series of product candidates. He has more than 20 years of drug discovery and project management experiences in large pharmaceutical companies such as Abbott, Amgen, Sunesis and KanionUSA and currently serves as chief executive officer of Viva Vision Biotech. He is the principle inventor of Lifitegrast (SAR1118), a potent LFA-1 inhibitor, approved by FDA to treat dry eye disease. Dr. Shen made important contributions to the development of to Venetoclax (ABT-199/GDC-0199), a selective BCL-2 inhibitor, approved by FDA in 2016 to treat certain types of leukemia. He is the co-author of over 40 peer-reviewed publications and co-inventor of over 40 patents.

Dr. Shen received his B.S. in chemistry from Fudan University and Ph.D. in Organic Chemistry from the University of Pittsburgh with Professor Dennis P. Curran and received his postdoctoral training at Memorial Sloan-Kettering Cancer Center under the direction of Prof. Samuel J. Danishefsky.